Evidence map›Paper›PMID 23052331›Full record

SynthesisClinical research in cardiology : official journal of the German Cardiac Society2013

Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review.

Paulino A Alvarez, Ernst R Schwarz, Rajesh Ramineni, Phil Myatt, Clay Barbin, Carlos Boissonnet, Anita Phan, Aldo Maggioni, Alejandro Barbagelata

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Investigating the role of acute mental stress on endothelial dysfunction: a systematic review and meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2015
    Pooled it
  2. Review
  3. Neonatal myocardial infarction: substantial improvement of cardiac function after autologous bone marrow-derived cell therapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Paulino A AlvarezHospital de Clínicas José de San Martin, Universidad de Buenos Aires, Buenos Aires, Argentina.
Ernst R Schwarz
Rajesh Ramineni
Phil Myatt
Clay Barbin
Carlos Boissonnet
Anita Phan
Aldo Maggioni
Alejandro Barbagelata
The University of Texas Medical Branch at Galveston · USAssociazione Nazionale Medici Cardiologi Ospedalieri · ITCentro de Educación Médica e Investigaciones Clínicas Norberto Quirno · ARUniversity of Buenos Aires · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell therapy (CTh) is a promising novel therapy for myocardial infarction (MI) and ischemic cardiomyopathy (iCMP). Recognizing adverse events (AE) is important for safety evaluation, harm prevention and may aid in the design of future trials.

objectiveTo define the prevalence of periprocedural AE in CTh trials in MI and iCMP.

methodsA literature search was conducted using the MEDLINE database from January 1990 to October 2010. Controlled clinical trials that compared CTh with standard treatment in the setting of MI and/or iCMP were selected. AE related to CTh were analyzed.

resultsA total of 2,472 patients from 35 trials were included. There were 26 trials including 1,796 patients that used CTh in MI and 9 trials including 676 patients that used CTh in iCMP. Periprocedural arrhythmia monitoring protocols were heterogeneous and follow-up was short in most of the trials. In MI trials, the incidence of periprocedural adverse events (AE) related to intracoronary cell transplantation was 7.5 % (95 % CI 6.04-8.96 %). AE related to granulocyte colony-stimulating factor (GCS-F) used for cell mobilization for peripheral apheresis was 16 % (95 % CI 9.44-22.56 %). During intracoronary transplantation in iCMP, the incidence of periprocedural AE incidence was 2.6 % (95 % CI 0.53-4.67 %). There were no AE reported during transepicardial transplantation and AE were rare during transendocardial transplantation.

conclusionsThe majority of periprocedural AE in CTh trials in MI occurred during intracoronary transplantation and GCS-F administration. In iCMP, periprocedural AE were uncommon. Avoiding intracoronary route for CTh implantation may decrease the burden of periprocedural AE. Standardization of AE definition in CTh trials is needed.

Indexed as

RegenerationCardiomyopathiesCell- and Tissue-Based TherapyHumansIncidenceMyocardial InfarctionMyocardiumOdds RatioPostoperative ComplicationsPrevalenceRisk AssessmentRisk FactorsTreatment Outcome

Identifiers

PMID23052331
OpenAlexW2075254090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.